

Taijyu Satoh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9754214/publications.pdf>

Version: 2024-02-01

16
papers

717
citations

623734

14
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

1048
citing authors

#	ARTICLE	IF	CITATIONS
1	Frataxin deficiency promotes endothelial senescence in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	38
2	Metabolic Syndrome Mediates ROS-miR-193b-NFYAâ€œDependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2021, 144, 615-637.	1.6	44
3	Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension. <i>Science Advances</i> , 2021, 7, eabh3794.	10.3	16
4	Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1543-1558.	2.4	20
5	ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure. <i>Circulation Research</i> , 2019, 125, 884-906.	4.5	52
6	Diagnostic and Prognostic Significance of Serum Levels of SeP (Selenoprotein P) in Patients With Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2553-2562.	2.4	12
7	Identification of Emetine as a Therapeutic Agent for Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2367-2385.	2.4	26
8	Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2019, 125, 309-327.	4.5	34
9	BOLA (Bola Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. <i>Circulation</i> , 2019, 139, 2238-2255.	1.6	54
10	Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 138, 600-623.	1.6	80
11	Small GTP-Binding Protein GDP Dissociation Stimulator Prevents Thoracic Aortic Aneurysm Formation and Rupture by Phenotypic Preservation of Aortic Smooth Muscle Cells. <i>Circulation</i> , 2018, 138, 2413-2433.	1.6	34
12	Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation Research</i> , 2017, 120, 1246-1262.	4.5	45
13	Protective Roles of Endothelial AMP-Activated Protein Kinase Against Hypoxia-Induced Pulmonary Hypertension in Mice. <i>Circulation Research</i> , 2016, 119, 197-209.	4.5	93
14	Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1293-1301.	2.4	35
15	Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 636-646.	2.4	47
16	Basigin Mediates Pulmonary Hypertension by Promoting Inflammation and Vascular Smooth Muscle Cell Proliferation. <i>Circulation Research</i> , 2014, 115, 738-750.	4.5	87